Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma.

The article presents a study on oral ibrutinib, a Bruton's tyrosine kinase (BTK), given to 111 refractory or relapsed mantle-cell lymphoma patients at 560 milligram (mg) daily dose. It says that the patients involved in the study were separated into two groups, one who were given at least two bortezomib therapy cycles and another who have not received such regime. It concludes that ibrutinib shows efficiency for treating the said condition.